-
公开(公告)号：US20180355063A1
公开(公告)日：2018-12-13
申请号：US15779428
申请日：2016-12-01
Applicant: UCB BIOPHARMA SPRL
Inventor： Helene Margaret FINNEY
CPC classification number: C07K16/468 , A61K2039/505 , A61K2039/572 , A61K2039/575 , A61P35/00 , C07K14/39 , C07K16/00 , C07K16/14 , C07K16/30 , C07K2317/31 , C07K2317/34 , C07K2317/52 , C07K2317/55 , C07K2317/569 , C07K2317/622 , C07K2317/73 , C07K2317/92 , C07K2319/00 , C07K2319/03 , C07K2319/035 , C07K2319/30 , C07K2319/33
Abstract: The present invention is directed to a method of controlling and directing cells, for example to stimulate an immune response, inhibit an immune response, direct tissue regeneration or prevent tissue damage for therapeutic activity through the use of heterodimerically-tethered bispecific protein complex of formula A-X:Y-B. Component A may present X on the surface of a cell, may bind a protein (including a marker) expressed on the surface of an effector cell, or A-X is expressed on the surface of an effector cell, whilst B is specific to an epitope on target cell or tissue of interest. X:Y is a heterodimeric-tether which is formed by a binding interaction between X and Y, which together with A and B assists and effects the controlling and directing of the selected cells.
-
公开(公告)号：US20160264668A1
公开(公告)日：2016-09-15
申请号：US15036209
申请日：2014-11-12
Applicant: UCB BIOPHARMA SPRL
Inventor： Paul Alan ATHERFOLD , Thomas Allen CESKA , Helene Margaret FINNEY , Lara KEVORKIAN , Kaushik SARKAR , Bryan John SMITH , Kerry Louise TYSON
CPC classification number: C07K16/283 , A61K47/60 , A61K47/6849 , A61K2039/505 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/55 , C07K2317/565 , C07K2317/624 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
Abstract translation: 本公开涉及对FcRn特异性的抗体，包含其的制剂，治疗中的每一种的使用，用于表达和任选配制所述抗体的方法，编码抗体的DNA和包含所述DNA的宿主。
-
公开(公告)号：US20190322739A1
公开(公告)日：2019-10-24
申请号：US16402097
申请日：2019-05-02
Applicant: UCB BIOPHARMA SPRL
Inventor： Helene Margaret FINNEY , Stephen Edward RAPECKI , Michael John WRIGHT
Abstract: The present disclosure relates to a novel bispecific protein complex and a method of using the complexes to screen for synergistic or novel biological function. The bispecific format is particularly suitable for high-throughput screening because all of its components can be expressed from cells as individual units and the units can be assembled simply by mixing without employing conjugation or coupling chemistry.
-
公开(公告)号：US20190270811A1
公开(公告)日：2019-09-05
申请号：US16299407
申请日：2019-03-12
Applicant: UCB BIOPHARMA SPRL
Inventor： Paul Alan ATHERFOLD , Thomas Allen CESKA , Helene Margaret FINNEY , Lara KEVORKIAN , Kaushik SARKAR , Bryan John SMITH , Kerry Louise TYSON
Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
-
Patent Agency Ranking
公开(公告)号：US20180273620A1
公开(公告)日：2018-09-27
申请号：US15743756
申请日：2016-07-15
Applicant: UCB Biopharma SPRL
Inventor： Helene Margaret FINNEY , Stephen Edward RAPECKI , Kerry Louise TYSON , Michael John WRIGHT
IPC: C07K16/28
Abstract: The present disclosure relates to antibody molecules comprising a binding domain specific to CD22, said binding domain comprising SEQ ID NO: 1, 2, 3, 4, 5 and 6 or 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.
-
公开(公告)号：US20180237521A1
公开(公告)日：2018-08-23
申请号：US15743761
申请日：2016-07-15
Applicant: UCB Biopharma SPRL
Inventor： Helene Margaret FINNEY , Stephen Edward RAPECKI , Kerry Louise TYSON , Michael John WRIGHT
CPC classification number: C07K16/289 , C07K16/18 , C07K16/2803 , C07K2317/24 , C07K2317/31 , C07K2317/35 , C07K2317/55 , C07K2317/622 , C07K2317/624 , C07K2317/64 , C07K2317/76 , C07K2317/90
Abstract: The present disclosure relates to constructs, such as antibody molecules comprising a binding domain specific to CD45, said binding domain comprising SEQ ID NO: 1, 2, 3 and/or SEQ ID NO: 4, 5 and 6. The disclosure also extends to pharmaceutical compositions comprising said constructs and use of the constructs/compositions in treatment.
-
公开(公告)号：US20180201678A1
公开(公告)日：2018-07-19
申请号：US15743764
申请日：2016-07-15
Applicant: UCB Biopharma SPRL
Inventor： Helene Margaret FINNEY , Stephen Edward RAPECKI , Kerry Louise TYSON , Michael John WRIGHT
IPC: C07K16/28
CPC classification number: C07K16/2803 , A61K47/6809 , A61K47/6849 , A61K47/6867 , C07K16/18 , C07K16/289 , C07K16/2896 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/35 , C07K2317/55 , C07K2317/622 , C07K2317/64 , C07K2317/76
Abstract: The present disclosure relates to antibody molecules comprising a binding domain specific to CD79, said binding domain comprising SEQ ID NO: 1, 2, 3 or 4, and/or SEQ ID NO: 5, 6 and 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.
-
公开(公告)号：US20220162311A1
公开(公告)日：2022-05-26
申请号：US17643506
申请日：2021-12-09
Applicant: UCB BIOPHARMA SPRL
Inventor： Paul Alan ATHERFOLD , Thomas Allen CESKA , Helene Margaret FINNEY , Lara KEVORKIAN , Kaushik SARKAR , Bryan John SMITH , Kerry Louise TYSON
Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
-
公开(公告)号：US20200024346A1
公开(公告)日：2020-01-23
申请号：US16513002
申请日：2019-07-16
Applicant: UCB BIOPHARMA SPRL
Inventor： Helene Margaret FINNEY , Stephen Edward RAPECKI , Michael John WRIGHT , Kerry Louise TYSON
Abstract: The present disclosure relates to multispecific molecule comprising a binding domain specific to the antigen CD22 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising the same and use of both in treatment, for example the treatment of autoimmune disease.
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.02 seconds)
